Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7916205rdf:typepubmed:Citationlld:pubmed
pubmed-article:7916205lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:7916205lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:7916205lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:7916205lifeskim:mentionsumls-concept:C0035015lld:lifeskim
pubmed-article:7916205lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:7916205lifeskim:mentionsumls-concept:C1332714lld:lifeskim
pubmed-article:7916205lifeskim:mentionsumls-concept:C0872192lld:lifeskim
pubmed-article:7916205lifeskim:mentionsumls-concept:C1882923lld:lifeskim
pubmed-article:7916205lifeskim:mentionsumls-concept:C1548437lld:lifeskim
pubmed-article:7916205lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:7916205lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:7916205lifeskim:mentionsumls-concept:C1706907lld:lifeskim
pubmed-article:7916205pubmed:issue6lld:pubmed
pubmed-article:7916205pubmed:dateCreated1994-10-20lld:pubmed
pubmed-article:7916205pubmed:abstractTextThis study showed that non-MHC genes common to (DBA/2 H-2d) and (DBA/1 H-2q) gave rise to suppressor T (Ts) cells in the hybrid F1 mice between C57BL/6 (B6) strain in the anti-FBL-3 tumor responses. FBL-3, a Friend virus-induced tumor cell line of B6 mouse origin, is highly immunogenic as shown by findings that syngeneic and hybrid F1 mice with several other inbred strains rejected up to 3 x 10(7) tumors cell inoculated s.c. and generated potent CTL responses after mixed lymphocyte tumor cell culture. In contrast to these mice, (B6 x DBA/2) and (B6 x DBA/1)F1 mice did not reject the tumor as the tumor doses increased. Progressive tumor growth in these F1 mice was blocked by an i.p. injection of cyclophosphamide (250 mg/kg) on day 10, but not on day 5, after tumor cell inoculation. Anti-CD4 (GK1.5) mAb exerted similar therapeutic effects against tumor when given twice, between day 0 and 10, whereas the additional injection of anti-CD8 mAb enhanced the tumor growth in mice that otherwise rejected the tumor. Thus, in the response of (B6 x DBA/2)F1 mice to FBL-3 tumor cells, CD4+ Ts seemed to down-regulate the immunologically mediated regression of the tumor produced by CD8+ CTL. This was evidenced by limiting dilution culture analyses, which showed that the frequency of an FBL-3-specific CTL precursor in the (B6 x DBA/2)F1 mice that rejected the tumor with anti-CD4 mAb was approximately 7- to 9-fold higher than that in mice in which the tumor regressed spontaneously.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:7916205pubmed:languageenglld:pubmed
pubmed-article:7916205pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7916205pubmed:citationSubsetIMlld:pubmed
pubmed-article:7916205pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7916205pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7916205pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7916205pubmed:statusMEDLINElld:pubmed
pubmed-article:7916205pubmed:monthJunlld:pubmed
pubmed-article:7916205pubmed:issn0953-8178lld:pubmed
pubmed-article:7916205pubmed:authorpubmed-author:TeramuraYYlld:pubmed
pubmed-article:7916205pubmed:authorpubmed-author:KuribayashiKKlld:pubmed
pubmed-article:7916205pubmed:authorpubmed-author:MoriokaAAlld:pubmed
pubmed-article:7916205pubmed:authorpubmed-author:IwashiroMMlld:pubmed
pubmed-article:7916205pubmed:authorpubmed-author:MatsubayashiY...lld:pubmed
pubmed-article:7916205pubmed:issnTypePrintlld:pubmed
pubmed-article:7916205pubmed:volume6lld:pubmed
pubmed-article:7916205pubmed:ownerNLMlld:pubmed
pubmed-article:7916205pubmed:authorsCompleteYlld:pubmed
pubmed-article:7916205pubmed:pagination839-46lld:pubmed
pubmed-article:7916205pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:meshHeadingpubmed-meshheading:7916205-...lld:pubmed
pubmed-article:7916205pubmed:year1994lld:pubmed
pubmed-article:7916205pubmed:articleTitleEffects of non-MHC background genes on the induction of CD4+ T cells that prevent rejection of a highly immunogenic tumor, FBL-3.lld:pubmed
pubmed-article:7916205pubmed:affiliationDepartment of Immunology and Cell Biology, Faculty of Medicine, Kyoto University, Japan.lld:pubmed
pubmed-article:7916205pubmed:publicationTypeJournal Articlelld:pubmed